End points and United States Food and Drug Administration approval of oncology drugs.
暂无分享,去创建一个
[1] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[2] R. Justice. FDA Role in Cancer Drug Development and Requirements for Approval , 1997 .
[3] R. Temple,et al. Food and Drug Administration requirements for approval of new anticancer drugs. , 1985, Cancer treatment reports.
[4] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.
[5] L. Norton. Kinetic concepts in the systemic drug therapy of breast cancer. , 1999, Seminars in oncology.
[6] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[7] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[8] R. Wittes,et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[10] P. Schein. The case for a new national program for the development of cancer therapeutics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.